These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 7000346

  • 1. CCNU, melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in the treatment of advanced breast cancer in postmenopausal women.
    Salimtschik M, Snel S, Havsteen H, Dombernowsky P, Mouridsen HT.
    Cancer Treat Rep; 1980; 64(4-5):635-7. PubMed ID: 7000346
    [Abstract] [Full Text] [Related]

  • 2. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G, Di Blasio B, Boni C, Bisagni G, Ceci G, Rondini E, Bella M, Leonardi F, Savoldi L, Camisa R, Bruzzi P.
    Cancer; 2002 Jul 15; 95(2):228-35. PubMed ID: 12124820
    [Abstract] [Full Text] [Related]

  • 3. Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group.
    Neoplasma; 1985 Jul 15; 32(3):381-7. PubMed ID: 2862594
    [Abstract] [Full Text] [Related]

  • 4. Recent progress in breast cancer management. Combined modality (adjuvant) therapy.
    Cowan K, Lippman M.
    Arch Intern Med; 1981 Jul 15; 141(8):1055-9. PubMed ID: 7018440
    [No Abstract] [Full Text] [Related]

  • 5. [Treatment of advanced breast cancer with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (CMFP)].
    Rabinovich MG, Leone BA, Landó O.
    Medicina (B Aires); 1981 Jul 15; 41(1):65-70. PubMed ID: 7266359
    [No Abstract] [Full Text] [Related]

  • 6. Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.
    Henderson IC, Gelman R, Canellos GP, Frei E.
    Cancer Treat Rep; 1981 Jul 15; 65 Suppl 1():67-75. PubMed ID: 6976832
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer.
    Mouridsen HT, Palshof T, Brahm M, Rahbek I.
    Cancer Treat Rep; 1977 Jul 15; 61(1):47-50. PubMed ID: 324620
    [Abstract] [Full Text] [Related]

  • 8. Combination chemotherapy with CCNU, melphalan, methotrexate, and prednisone (CAMP) in 35 patients with advanced breast cancer.
    Hansen M, Palshof T, Osterlind K, Hansen HH, Mouridsen H.
    Cancer Treat Rep; 1977 Nov 15; 61(8):1603-5. PubMed ID: 922762
    [No Abstract] [Full Text] [Related]

  • 9. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD, Jolivet J, Birch R, Hopkins LG, Greco FA.
    Cancer; 1997 Feb 15; 79(4):740-8. PubMed ID: 9024712
    [Abstract] [Full Text] [Related]

  • 10. CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.
    Mouridsen HT, Palshof T, Engelsman E, Sylvester R.
    Eur J Cancer (1965); 1980 Feb 15; Suppl 1():119-23. PubMed ID: 7032921
    [No Abstract] [Full Text] [Related]

  • 11. [Chemotherapy in curable breast cancer].
    Seradour B, Thomas M.
    J Gynecol Obstet Biol Reprod (Paris); 1978 Mar 15; 7(2):175-82. PubMed ID: 353124
    [No Abstract] [Full Text] [Related]

  • 12. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC, Norton L, Cancer and Leukemia Group B.
    J Clin Oncol; 2003 May 01; 21(9):1825-35. PubMed ID: 12721260
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N, National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol; 2005 Aug 01; 23(22):5166-70. PubMed ID: 16051958
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S.
    Cancer; 2003 Jan 01; 97(1):21-9. PubMed ID: 12491501
    [Abstract] [Full Text] [Related]

  • 20. [Results of "5-drug" treatment of advanced breast cancer].
    Dorociak R.
    Pol Tyg Lek; 1981 Sep 21; 36(38):1467-70. PubMed ID: 7329862
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.